Last update Oct. 1, 2023

Тегасерода Малеат

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Pro-kinetic and selective agonist drug of 5-HT4 receptor of serotonin that may enhance bowel and colon motility. Indicated for treatment of irritable colon syndrome with predominant constipation. Oral administration twice daily.

At the time of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (very large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

Its low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk, except in premature infants and the immediate neonatal period where there may be greater intestinal permeability.

It has been withdrawn from most countries due to an apparent high incidence of cardiovascular ischemic events. (Sayuk 2023)


  • Linaclotide (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Тегасерода Малеат is Tegaserod Maleate in Cyrillic.

Is written in other languages:


Тегасерода Малеат belongs to this group or family:


Main tradenames from several countries containing Тегасерода Малеат in its composition:


Variable Value Unit
Oral Bioavail. 10 %
Molecular weight 418 daltons
Protein Binding 98 %
VD 5.3 ± 3.2 l/Kg
pKa 15.24 -
Tmax 1 (0.7 - 2) hours
4.6 - 8.1 hours


  1. Sayuk GS, Tack J. Tegaserod: What's Old Is New Again. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2175-2184.e19. Abstract
  2. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM